Stock LPCN LIPOCINE INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Lipocine Inc.

Equities

LPCN

US53630X2036

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
6.04 USD +5.04% Intraday chart for Lipocine Inc. +13.53% +116.49%
May. 09 Earnings Flash (LPCN) LIPOCINE Reports Q1 Revenue $7.6M MT
May. 09 Lipocine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Earnings Flash (LPCN) LIPOCINE Reports Q1 Revenue $7.6M
MT
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024
PR
Lipocine: Q1 Earnings Snapshot
AQ
Lipocine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
PR
Lipocine : Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024 - Form 8-K
PU
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
PR
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
CI
Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial
MT
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
AQ
Top Premarket Gainers
MT
Lipocine Inc. Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
CI
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
PR
Lipocine Inc. Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
CI
Lipocine Doses First Group in Pivotal Study of Potential Postpartum Depression Drug
MT
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
PR
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
CI
Lipocine : Announces First Cohort Dosed in Pivotal Study of LPCN 1154 - Form 8-K
PU
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
AQ
Lipocine : Announces Financial Results for the Full Year Ended December 31, 2023 - Form 8-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LPCN Stock
  4. News Lipocine Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW